KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Liabilities (2018 - 2025)

Castle Biosciences' Total Liabilities history spans 7 years, with the latest figure at $107.7 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 42.82% year-over-year to $107.7 million; the TTM value through Dec 2025 reached $107.7 million, up 42.82%, while the annual FY2025 figure was $107.7 million, 42.82% up from the prior year.
  • Total Liabilities for Q4 2025 was $107.7 million at Castle Biosciences, up from $95.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $107.7 million in Q4 2025 and bottomed at $18.7 million in Q1 2021.
  • The 5-year median for Total Liabilities is $50.5 million (2021), against an average of $55.6 million.
  • The largest annual shift saw Total Liabilities plummeted 55.34% in 2021 before it surged 151.49% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $50.8 million in 2021, then decreased by 5.22% to $48.2 million in 2022, then rose by 28.83% to $62.1 million in 2023, then rose by 21.47% to $75.4 million in 2024, then skyrocketed by 42.82% to $107.7 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Total Liabilities are $107.7 million (Q4 2025), $95.7 million (Q3 2025), and $89.4 million (Q2 2025).